

RECEIVED

SEP 16 2002

SEP 18 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **TECH CENTER 1600/2900**  
Patents, Washington, D.C. 20231.

**Typed or Printed Name**

Kimberly W. Zuehlke

**Signature**

Date \_\_\_\_\_

11 September 2002

## AMENDMENT

Application No.

09/819,094

Confirmation No. \_\_\_\_\_

6968

Filing Date

March 27, 2001

First Named Inventor

Richard I Weiner

Examiner

Michael T. Brannock

## Group Art Unit

1646

DOCKET No.

UCSF-264CON

Sir:

**This amendment is responsive to the Restriction/Election Requirement dated August 12, 2002 for which a one month period for response was given making this response timely filed on or before September 12, 2002.**

**Please amend the application as follows:**

## AMENDMENTS

**IN THE CLAIMS:**

Please amend claims 1-5 as shown in the attached “VERSION WITH MARKINGS TO SHOW CHANGES MADE.” Further, please add the following new claims 27-30. Please cancel claims 6-26 without prejudice to the filing of a divisional application directed to any of these claims or any other invention disclosed and described in this application.

1. (Amended) An isolated anti-angiogenic peptide substantially identical to about 10 to about 150 consecutive amino acids selected from the N-terminal end of human placental lactogen, human growth hormone, or growth hormone variant hGH-V, wherein the peptide

- (i) inhibits capillary endothelial cell proliferation and organization;
- (ii) inhibits angiogenesis in chick chorioallantoic membrane; and
- (iii) binds to at least one specific receptor which does not bind to intact full length growth hormone, placental lactogen, or growth hormone variant hGH-V.

2. (Amended) The isolated peptide of claim 1, wherein the peptide is generated by enzymatic